Frank Harrell on why and how to do Bayes for clinical trials and the recent FDA draft guidelines

Witold, Erik, and I just published a paper in JAMA commenting on the recent FDA draft guidelines for the use of Bayesian methods in clinical trials. Earlier today I posted links and my reactions to two other comments on these … Continue reading →